Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
AK104+anlotinib
DRUG
2 trials
Sponsors
Chinese PLA General Hospital
, Akeso
Conditions
NSCLC
Non-small Cell Lung Cancer
Phase 1
A Trial of AK104 Plus Anlotinib in NSCLC
Completed
NCT04646330
Akeso
NSCLC
Start: 2020-11-18
End: 2025-07-30
Updated: 2025-08-19
Phase 2
A Study of Combination Therapy in NSCLC
NCT04544644
Chinese PLA General Hospital
Non-small Cell Lung Cancer
Start: 2020-09-30
End: 2023-09-30
Target: 30
Updated: 2020-09-10
Related Papers
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
2023-12-18
26 citations